Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects~* Have a body weight between 60.0 and 94.9 kg and a body mass index between 18.0 and 29.9 kg/m², inclusive.~Exclusion Criteria:~* history of and/or current clinically significant gastrointestinal, renal, hepatic, cardiovascular, haematological (including pancytopenia, aplastic anaemia or blood dyscrasia), pulmonary, neurologic, metabolic (including known diabetes mellitus), psychiatric or significant allergic disease excluding mild asymptomatic allergies.~* history of and/or current cardiac disease~* previously received any monoclonal antibody or fusion protein.~* history of cancer including lymphoma, leukaemia and skin cancer.~* Have received live vaccine(s) within 30 days prior to Screening or who will require a vaccine(s) between Screening and the End of Study visit.~* intake medication with a half-life \> 24 h within 1 month or 10 half-lives of the medication prior to the administration of investigational product.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- SB3 (Type: EXPERIMENTAL): SB3, single dose of 6 mg/kg via intravenous infusion (study drug)
- EU sourced Herceptin® (Type: ACTIVE_COMPARATOR): EU sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)
- US sourced Herceptin® (Type: ACTIVE_COMPARATOR): US sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)

Based on this trial design, predict the completion outcome and termination type (if applicable).